JPMorgan Chase & Co. Makes New Investment in SCYNEXIS, Inc. (NASDAQ:SCYX)

JPMorgan Chase & Co. bought a new position in shares of SCYNEXIS, Inc. (NASDAQ:SCYX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 40,199 shares of the company’s stock, valued at approximately $49,000. JPMorgan Chase & Co. owned about 0.11% of SCYNEXIS at the end of the most recent reporting period.

Separately, Geode Capital Management LLC grew its position in shares of SCYNEXIS by 10.0% in the 3rd quarter. Geode Capital Management LLC now owns 398,856 shares of the company’s stock valued at $594,000 after buying an additional 36,405 shares during the last quarter. Hedge funds and other institutional investors own 54.37% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com started coverage on SCYNEXIS in a research report on Thursday, May 1st. They set a “hold” rating for the company.

SCYNEXIS Stock Performance

Shares of NASDAQ SCYX opened at $0.96 on Thursday. The company’s 50 day moving average price is $0.95 and its 200-day moving average price is $1.11. SCYNEXIS, Inc. has a 52-week low of $0.73 and a 52-week high of $3.07. The company has a market capitalization of $37.47 million, a P/E ratio of -1.30 and a beta of 1.65.

SCYNEXIS (NASDAQ:SCYX) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%. The business had revenue of $0.98 million for the quarter.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.